Ashwagandha Cuts Body Weight by 8.5 kg and Slashes Stress Over 24 Weeks

Chronic stress and excess body weight form a self-reinforcing cycle: stress elevates cortisol, which promotes visceral fat accumulation, increases appetite, and drives cravings for calorie-dense comfort foods — all of which worsen stress further. Breaking this cycle is a central challenge in metabolic health. Ashwagandha (Withania somnifera), a well-characterized adaptogenic herb used in Ayurvedic medicine, has demonstrated stress-reducing and cortisol-lowering effects in prior studies, making it a plausible candidate for combined stress and weight management.

This prospective, randomized, double-blind, placebo-controlled trial enrolled 100 adults aged 19–65 with BMI between 25.0 and 39.9 kg/m² at a single center in Mumbai, India. Participants were randomized 1:1 to receive either 300 mg of standardized KSM-66 Ashwagandha root extract (>5% withanolides by HPLC) or an identical starch placebo twice daily for 24 weeks. No specific dietary or exercise modifications were prescribed. Assessments occurred at baseline, week 4, week 12, and week 24. The final efficacy analysis included 91 participants (45 ARE, 46 placebo).

For the primary endpoints, ARE produced a mean body weight reduction of 8.46 ± 3.86 kg compared to 2.41 ± 2.07 kg with placebo — a difference of roughly 6 kg (P < 0.0001, Cohen's d = –1.919, indicating a large effect size). BMI fell by 3.31 ± 1.57 kg/m² with ARE versus 0.93 ± 0.79 kg/m² with placebo (P < 0.0001). Significant divergence between groups was already apparent at week 4 and continued to widen through week 24. For secondary endpoints, ARE led to statistically significant improvements versus placebo in perceived stress (PSS-10), health-related quality of life (SF-12 physical and mental component summaries), food craving intensity (FCQ-T), and subjective satisfaction (SSS), all at P < 0.05.

Safety data were reassuring. Seven participants in the ARE group and six in the placebo group reported mild, transient adverse events (nausea, abdominal pain, drowsiness), all resolving without intervention. Comprehensive laboratory panels — including complete blood count, liver function tests, renal function tests, lipid profile, thyroid hormones (T3/T4), fasting glucose, and HbA1c — showed no clinically meaningful changes from baseline in either group, confirming a favorable safety profile over six months of use.

The proposed mechanism centers on ARE's modulation of the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol secretion and thereby attenuating stress-driven appetite stimulation and fat storage. Complementary antioxidant, anti-inflammatory, and metabolic-enhancing properties of withanolides may further support fat utilization over fat storage. While the results are compelling, the single-center design, relatively short 24-week duration, absence of direct cortisol measurement at all timepoints (reported at baseline, weeks 4, 12, and 24 but results not fully detailed in the available text), and lack of dietary monitoring are important caveats. Independent replication in larger, multicenter populations would strengthen confidence in these findings.